Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Definitions

• the present invention relates to a composition for use in living organisms.
• Symptomatic treatments for stomatitis include patches that are applied directly to the affected area (e.g., Aphthaseal® 25 ⁇ g, manufactured by Taisho Toyama Pharmaceutical Co., Ltd.; active ingredient: triamcinolone acetonide), ointments that are applied to the affected area (e.g., Dexaltin Oral Ointment, manufactured by Nippon Kayaku Co., Ltd.; active ingredient: dexamethasone), and sprays that are sprayed onto the affected area (e.g. , Salcoat® Capsules for External Use 50 ⁇ g, manufactured by Teijin Pharma Limited; active ingredient: beclomethasone propionate).
• Aphthaseal® 25 ⁇ g manufactured by Taisho Toyama Pharmaceutical Co., Ltd.
• active ingredient triamcinolone acetonide
• ointments that are applied to the affected area
• dexaltin Oral Ointment manufactured by Nippon Kayaku Co., Ltd.
• the patch attached to the affected area may come off or the ointment or spray applied to the affected area may be lost, so the pain of the stomatitis cannot be adequately suppressed.
• an alkyl glyceryl ether-containing composition that contains (A) one or more alkyl glyceryl ethers selected from the group consisting of chimyl alcohol, batyl alcohol, and selachyl alcohol, (B) lecithin, (C)
• the present invention aims to provide a composition for use in living organisms that can form a film when in contact with water and that has excellent elastic modulus and strain resistance.
• a compound X selected from the group consisting of ⁇ -monoalkyl glyceryl ethers and ⁇ -monoalkenyl glyceryl ethers; Phospholipids and and a compound Y selected from the group consisting of alcohols having 4 or less carbon atoms and polyalkylene oxides,
• a composition for living organisms wherein the content of the compound Y is 1 to 10% by mass based on the total mass of the compound X and the phospholipid.
• content of the compound X is 50% by mass or more based on the total mass of the composition for living organisms.
• composition for living organisms according to any one of [1] to [6] which forms an inverted hexagonal columnar phase upon water or moisture absorption.
• composition for living organisms according to any one of [1] to [7] which is for use on the skin or mucosa.
• the present invention provides a composition for use in living organisms that can form a film when in contact with water, and the film formed has excellent elastic modulus and strain resistance.
• a numerical range expressed using “to” means a range that includes the numerical values before and after “to” as the lower and upper limits.
• the “content” of the component means the total content of those two or more components.
• the upper limit or lower limit described in a certain numerical range may be replaced with the upper limit or lower limit of another numerical range described stepwise.
• the upper limit or lower limit described in a certain numerical range may be replaced with a value shown in the examples.
• a combination of two or more preferred aspects is a more preferred aspect.
• composition for living organisms contains a compound X selected from the group consisting of ⁇ -monoalkyl glyceryl ethers and ⁇ -monoalkenyl glyceryl ethers, a phospholipid, and a compound Y selected from the group consisting of an alcohol having 4 or less carbon atoms and a polyalkylene oxide, and the content of compound Y is 1 to 10% by mass based on the total mass of compound X and the phospholipid.
• a compound X selected from the group consisting of ⁇ -monoalkyl glyceryl ethers and ⁇ -monoalkenyl glyceryl ethers
• a phospholipid a compound Y selected from the group consisting of an alcohol having 4 or less carbon atoms and a polyalkylene oxide
• the content of compound Y is 1 to 10% by mass based on the total mass of compound X and the phospholipid.
• composition for living organisms having the above-mentioned configuration can solve the problems of the present invention is not necessarily clear, but the present inventors speculate as follows.
• the mechanism by which the effects are obtained is not limited by the following speculation. In other words, even if the effects are obtained by a mechanism other than the following, it is included in the scope of the present invention.
• the composition for living bodies of the present invention contains a compound X selected from the group consisting of ⁇ -monoalkyl glyceryl ethers and ⁇ -monoalkenyl glyceryl ethers, and a compound Y selected from the group consisting of a phospholipid, an alcohol having 4 or less carbon atoms, and a polyalkylene oxide, and is therefore capable of forming a film (preferably a film exhibiting a liquid crystal phase) having excellent bioadhesiveness and strength (e.g., elastic modulus and strain resistance) when contacted with water.
• a film preferably a film exhibiting a liquid crystal phase
• bioadhesiveness and strength e.g., elastic modulus and strain resistance
• composition for living organisms of the present invention contains a compound X selected from the group consisting of ⁇ -monoalkyl glyceryl ethers and ⁇ -monoalkenyl glyceryl ethers.
• the alkyl group in the ⁇ -monoalkyl glyceryl ether preferably has 6 to 32 carbon atoms, more preferably 10 to 24 carbon atoms, and even more preferably 16 to 18 carbon atoms.
• the alkenyl group in the ⁇ -monoalkenyl glyceryl ether preferably has 6 to 32 carbon atoms, more preferably 10 to 24 carbon atoms, and even more preferably 16 to 18 carbon atoms.
• the number of double bonds in the alkenyl group is not particularly limited as long as it is 1 or more, but 1 to 3 is preferable, and 1 is more preferable.
• the above alkyl and alkenyl groups may each be either linear or branched, with linear groups being preferred.
• alkyl group and alkenyl group examples include an oleyl group, a stearyl group, a cetyl group, a lauryl group, a tridecyl group, a myristyl group, a pentadecyl group, and a monoisostearyl group. It is also preferred that compound X is an ⁇ -monoalkenyl glyceryl ether.
• compound X examples include selachyl alcohol ( ⁇ -monooleyl glyceryl ether), batyl alcohol ( ⁇ -monostearyl glyceryl ether), chimyl alcohol ( ⁇ -monocetyl glyceryl ether), ⁇ -monolauryl glyceryl ether, ⁇ -monotridecyl glyceryl ether, ⁇ -monomyristyl glyceryl ether, ⁇ -monopentadecyl glyceryl ether, and ⁇ -monoisostearyl glyceryl ether.
• Selachyl alcohol, batyl alcohol, or chimyl alcohol is preferred, and selachyl alcohol is more preferred.
• compound X is preferably selected from the group consisting of selachyl alcohol, batyl alcohol, and chimyl alcohol, and more preferably selachyl alcohol.
• Compound X may be used alone or in combination of two or more thereof.
• Compound X may be used in combination of ⁇ -monoalkyl glyceryl ether and ⁇ -monoalkenyl glyceryl ether.
• the content of compound X is preferably 30% by mass or more, more preferably 45% by mass or more, and even more preferably 50% by mass or more, based on the total mass of the composition for living bodies.
• the content of compound X is preferably 90% by mass or less, more preferably 80% by mass, even more preferably 70% by mass or less, and particularly preferably 65% by mass or less, based on the total mass of the composition for living bodies.
• the content of compound X means the total content of ⁇ -monoalkyl glyceryl ether and ⁇ -monoalkenyl glyceryl ether contained in the composition for living organisms.
• the above liquid viscosity is the viscosity of the composition for living organisms before it comes into contact with water, and from the viewpoints of ease of application and excellent usability, a low liquid viscosity is preferable.
• the composition for living organisms of the present invention has a high film-forming rate.
• the film-forming rate may also correspond to the rate of formation of a liquid crystal film (a film containing a liquid crystal phase), i.e., the rate of formation of a liquid crystal phase.
• the composition for living bodies of the present invention contains a phospholipid.
• the phospholipid is not particularly limited as long as it has a phosphate ester structure in its molecular structure, but representative examples include glycerophospholipids with glycerin as the backbone and sphingophospholipids with sphingosine as the backbone. Both glycerophospholipids and sphingophospholipids have an acyl group derived from a fatty acid in the molecule.
• the number of carbon atoms in the acyl group of the phospholipid is not particularly limited, but is preferably 12 to 22, and more preferably 16 to 18.
• the hydrocarbon group excluding the carbonyl group of the acyl group is preferably a saturated or unsaturated chain hydrocarbon group having 11 to 21 carbon atoms, more preferably a saturated or unsaturated chain hydrocarbon group having 15 to 17 carbon atoms.
• Specific examples of the hydrocarbon group include, but are not limited to, CH 3 (CH 2 ) 14 -, CH 3 (CH 2 ) 7 CH ⁇ CH(CH 2 ) 7 -, and CH 3 (CH 2 ) 4 (CH ⁇ CHCH 2 ) 2 (CH 2 ) 6 -.
• the acyl groups may be the same as or different from each other.
• phospholipids examples include phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidic acid, phosphatidylglycerol, sphingomyelin, and sphingoethanolamine.
• the phospholipid preferably contains an ionic phospholipid, since the water absorption rate of the composition for living bodies of the present invention is improved and a columnar layer with a large domain size is easily formed.
• the water absorption rate means the rate at which the composition for living bodies of the present invention absorbs water or moisture.
• a high water absorption rate is preferable, since the film formation rate and the effect of the present invention are more excellent.
• Ionic phospholipids include phospholipids having a cationic moiety and an anionic moiety in one molecule, such as phosphatidylcholine.
• Phosphatidylcholine is a phospholipid having an N + group derived from choline as the cationic moiety and a P-O- group derived from phosphoric acid as the anionic moiety.
• phosphatidylcholine examples include PO phosphatidylcholine (phosphatidylcholine having an acyl group derived from palmitic acid at position 1 ( ⁇ -position), an acyl group derived from oleic acid at position 2 ( ⁇ -position), and choline at position 3 ( ⁇ -position)), DL phosphatidylcholine (phosphatidylcholine having an acyl group derived from linoleic acid at position 1 ( ⁇ -position), an acyl group derived from linoleic acid at position 2 ( ⁇ -position), and choline at position 3 ( ⁇ -position)), and dipalmitoylphosphatidylcholine.
• PO phosphatidylcholine phosphatidylcholine having an acyl group derived from palmitic acid at position 1 ( ⁇ -position), an acyl group derived from oleic acid at position 2 ( ⁇ -position), and choline at position 3 ( ⁇ -position)
• the phospholipid comprises a phosphatidylcholine.
• the content of the phosphatidylcholine is preferably 50% by mass or more, more preferably 75% by mass or more, and even more preferably 90% by mass or more, based on the total mass of the phospholipid.
• the upper limit of the content of the phosphatidylcholine based on the total mass of the phospholipid is not particularly limited, and may be 100% by mass, and is often 99% by mass or less.
• a composition containing phospholipids may be used, specifically, for example, a composition containing phosphatidylcholine may be used.
• the content of phosphatidylcholine in the composition containing phosphatidylcholine is preferably 75% by mass or more, more preferably 90% by mass or more, based on the total mass of the composition containing phosphatidylcholine.
• the phospholipids may be used alone or in combination of two or more kinds.
• the mass ratio of the content of compound X to the content of phospholipid is preferably 95/5 to 20/80, more preferably 80/20 to 40/60, even more preferably 70/30 to 50/50, and particularly preferably 65/35 to 55/45.
• the content of the phospholipid is preferably 5 to 80 mass %, more preferably 20 to 50 mass %, and even more preferably 30 to 45 mass %, based on the total mass of the composition for living organisms.
• composition for living organisms of the present invention contains a compound Y selected from the group consisting of alcohols having 4 or less carbon atoms and polyalkylene oxides.
• Alcohols having up to 4 carbon atoms and polyalkylene oxides can function as solvents for compound X and the phospholipid.
• the alcohol having 4 or less carbon atoms and the polyalkylene oxide are preferably biocompatible.
• the alcohol having 4 or less carbon atoms is a compound having at least one hydroxyl group bonded to an aliphatic hydrocarbon group having 4 or less carbon atoms. If the alcohol has 5 or more carbon atoms, it is not preferable because its function as a solvent for compound X and phospholipids is reduced and the solubility becomes insufficient.
• the aliphatic hydrocarbon group having 4 or less carbon atoms may be linear, branched, or cyclic, but is preferably linear or branched.
• the number of carbon atoms in the alcohol having 4 or less carbon atoms is not particularly limited as long as it is 4 or less, but is preferably 3 or less.
• the lower limit of the number of carbon atoms in the alcohol having 4 or less carbon atoms is 1 or more, preferably 2 or more, and more preferably 3 or more.
• the number of hydroxyl groups in the alcohol having 4 or less carbon atoms is not particularly limited as long as it is 1 or more, but 1 or 2 is preferred.
• alcohols having 4 or less carbon atoms include monoalcohols such as ethanol, propanol, isopropanol, and butanol; glycols (dialcohols) such as ethylene glycol, propylene glycol, butylene glycol, and 1,3-butylene glycol; and glycerol.
• monoalcohols such as ethanol, propanol, isopropanol, and butanol
• glycols dialcohols
• ethylene glycol, propylene glycol, butylene glycol, and 1,3-butylene glycol such as ethylene glycol, propylene glycol, butylene glycol, and 1,3-butylene glycol
• glycerol examples of alcohols having 4 or less carbon atoms
• Ethanol, isopropanol, ethylene glycol, 1,3-butylene glycol, and propylene glycol are preferred, and ethanol, 1,3-butylene glycol, and propylene glycol are
• a polyalkylene oxide is a polymer having an oxyalkylene group as a repeating unit.
• the terminal of the polyalkylene oxide may be either an alkyl group or a hydroxyl group.
• the polyalkylene oxide may have hydroxy groups, and the number of hydroxy groups is not particularly limited.
• the number of carbon atoms in the alkylene group of the polyalkylene oxide is not particularly limited, but is preferably 1 to 4.
• Examples of the oxyalkylene group include an oxyethylene group and an oxypropylene group.
• the polyalkylene oxide may be either linear or branched.
• the oxyalkylene groups in the polyalkylene oxide may be the same or different from one another.
• the polyalkylene oxide may be a polymer having both an oxyethylene group and an oxypropylene group as repeating units.
• Examples of polyalkylene oxides include polyoxyethylene polyols, polyoxypropylene polyols, and polyoxyethyleneoxypropylene polyols.
• Compound Y may be used alone or in combination of two or more. Compound Y may be used in combination of an alcohol having 4 or less carbon atoms and a polyalkylene oxide.
• the content of compound Y is 1 to 10% by mass based on the total mass of compound X and the phospholipid. If the content of compound Y is less than 1% by mass relative to the total mass of compound X and the phospholipid, this is not preferred because the composition is not homogenized and a film cannot be formed, whereas if it exceeds 10% by mass, this is not preferred because the strain resistance is deteriorated.
• the content of compound Y means the total content of the alcohol having 4 or less carbon atoms and the polyalkylene oxide contained in the composition for living bodies.
• the content of compound Y is preferably 3 to 8 mass % based on the total mass of compound X and the phospholipid.
• the content of compound Y is preferably 1 to 9 mass %, more preferably 3 to 8 mass %, based on the total mass of the composition for living organisms.
• the composition for living bodies of the present invention may contain water.
• the water content is preferably 0 to 10 mass%, more preferably 0 to 5 mass%, even more preferably 0 to 1 mass%, and particularly preferably 0 mass%, relative to the total mass of the composition for living organisms.
• composition for living bodies of the present invention may further contain a quaternary ammonium salt (excluding phosphatidylcholine).
• the quaternary ammonium salt is preferably an ionic compound comprising a positively charged polyatomic ion (quaternary ammonium cation) represented by the molecular formula NR 4 + and an anion.
• Each R independently represents an alkyl group which may have a substituent, an alkenyl group which may have a substituent, or an aryl group, and multiple Rs may be the same or different.
• Substituents that the alkyl and alkenyl groups may have include hydroxyl, acyloxy, acyl, alkoxy, alkenyloxy, and aryl groups.
• the hydrocarbon groups that the acyloxy and acyl groups have are preferably long-chain alkyl groups (alkyl groups having 8 or more carbon atoms) or long-chain alkenyl groups (alkenyl groups having 8 or more carbon atoms).
• the anion is not particularly limited, and examples thereof include an acid anion, a halide ion, and a hydroxide ion.
• Di-long-chain alkyl quaternary ammonium salts and di-long-chain alkenyl quaternary ammonium salts are salts in which two of the Rs in the quaternary ammonium cation represented by the molecular formula NR 4 + are long-chain alkyl groups (alkyl groups having 8 or more carbon atoms) or long-chain alkenyl groups (alkenyl groups having 8 or more carbon atoms), and the other two Rs are each independently a short-chain alkyl group (alkyl groups having 1 to 7 carbon atoms) or an aryl group.
• the number of carbon atoms in the long-chain alkyl group and the long-chain alkenyl group is preferably 12 to 22, and more preferably 16 to 18.
• the two long-chain alkyl groups may be the same or different, and the two long-chain alkenyl groups may be the same or different.
• quaternary ammonium salts include dioleoyloxytrimethylammonium propane chloride (DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), dioctadecenyltrimethylammonium propane chloride (DOTMA, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), didecyldimethylammonium chloride, didecyldimethylammonium bromide, dilauryldimethylammonium chloride, dicetyldimethylammonium chloride, dicetyldimethylammonium bromide, distearyldimethylammonium chloride, distearyldimethylammonium bromide, dioleyldimethylammonium chloride, dibehenyldimethylammonium chloride, dibehenyldi
• the composition for living bodies of the present invention preferably forms a liquid crystal phase by coming into contact with water and absorbing water or moisture. Due to the formation of the liquid crystal phase, the film formed by the composition for living bodies of the present invention exhibits excellent elastic modulus and strain resistance.
• moisture absorption refers to absorbing moisture. Examples of moisture include water in the air and water in breath. In this specification, water absorption refers to absorbing water (excluding moisture).
• the thickness of the film formed by the composition for living bodies of the present invention is not particularly limited, but is, for example, 0.1 ⁇ m to 1 mm, and preferably 1 to 100 ⁇ m.
• water examples include water in the atmosphere (humidity), water in exhaled breath (humidity), pure water, and water contained in aqueous fluids other than water, such as saliva, tissue fluid, blood, and lymph.
• the amount of water to be contacted with the composition for living bodies of the present invention is not particularly limited, but is preferably 1000% by mass or less, more preferably 500% by mass or less, based on the total mass of the composition for living bodies of the present invention.
• the lower limit of the amount of water to be used when contacting the composition for living bodies of the present invention with the composition for living bodies of the present invention is not particularly limited, but may be, for example, more than 1% by mass.
• the temperature at which the composition for living organisms of the present invention is brought into contact with water is not particularly limited, but is preferably 20 to 40°C, more preferably 35 to 40°C.
• the liquid crystal phase that can be formed by contacting the composition for living bodies of the present invention with water is not particularly limited, but is often any one selected from the group consisting of a reverse hexagonal columnar (H2) phase (W/O hexagonal columnar phase), a hexagonal columnar (H1) phase (O/W hexagonal columnar phase), a lamellar (La) phase, a sponge (V2) phase, a bicontinuous cubic (L3) phase, and a mixed state of two or more of these.
• the above liquid crystal phase preferably has a reverse hexagonal columnar (H2) phase or a hexagonal columnar (H1) phase.
• composition for living organisms of the present invention preferably forms an inverted hexagonal columnar (H2) phase upon water or moisture absorption, and more preferably forms an inverted hexagonal columnar (H2) phase upon moisture absorption.
• composition for living bodies of the present invention may undergo a phase transition of the liquid crystal phase by absorbing further water after absorbing moisture.
• phase transition examples include a phase transition from an inverse hexagonal columnar (H2) phase to a hexagonal columnar (H1) phase.
• the liquid crystal phase may transition to another liquid crystal phase (e.g., a hexagonal columnar (H1) phase) by absorbing a larger amount of water than the water (humidity) in the atmosphere, such as water sprayed by a spray, artificial saliva, aqueous fluids, exudates from the skin, and water from eating and drinking.
• a small amount of water such as water in the atmosphere or water in breath
• the liquid crystal phase may transition to another liquid crystal phase (e.g., a hexagonal columnar (H1) phase) by absorbing a larger amount of water than the water (humidity) in the atmosphere, such as water sprayed by a spray, artificial saliva, aqueous fluids, exudates from the skin, and water from eating and drinking.
• composition for living organisms of the present invention can be produced, for example, by mixing compound X, phospholipid, compound Y, and, if necessary, optional components in a predetermined mixing ratio.
• the mixing method is not particularly limited, and any conventionally known method can be used.
• composition for living bodies of the present invention can be used in living bodies.
• the composition for living bodies of the present invention can be used for the purpose of supporting or repairing parts of a living body that are no longer performing their original functions due to injury or illness (e.g., objects such as skin, hair, and mucous membranes; the same applies below to "parts") and parts with reduced functions.
• the composition for living bodies of the present invention can be preferably used for the skin or mucous membranes (particularly for protecting the oral mucosa and digestive tract).
• a method for using the composition for living bodies of the present invention includes, for example, placing the composition for living bodies of the present invention on an area having symptoms as described above, and then contacting the composition for living bodies of the present invention with water.
• the composition for living bodies of the present invention When the composition for living bodies of the present invention is used on the skin, for example, the composition for living bodies of the present invention may be applied to the skin in the atmosphere, and water or a solution containing water may be added to the composition for living bodies of the present invention as necessary.
• the biological composition of the present invention on the skin can form a film (preferably a liquid crystal film) by contacting it with, for example, water in the atmosphere, water sprayed by a spray, any of the above-mentioned aqueous fluids, and exudates from the skin.
• composition for living bodies of the present invention When the composition for living bodies of the present invention is used on mucous membranes, the composition for living bodies of the present invention is placed on the mucous membrane, and water or a solution containing water is added to the composition for living bodies of the present invention as necessary.
• the biological composition of the present invention on the mucous membrane can form a film (preferably a liquid crystal film) by contacting with, for example, water in the atmosphere, water in exhaled breath, water sprayed by a spray, any of the aqueous fluids mentioned above, and water from eating and drinking.
• composition for living bodies of the present invention when the composition for living bodies of the present invention is applied to the oral mucosa, the composition for living bodies of the present invention is attached (applied) to the oral mucosa, and a film is formed by contacting with any of water in the air, water in the breath, and water in saliva, making handling easy. Also, if the amount of saliva is small, water can be supplied by spraying water or artificial saliva after the composition for living bodies of the present invention is attached to the oral mucosa.
• NIKKOL Selachyl alcohol V manufactured by Nikko Chemicals
• Compound X Phospholipid LIPOID P100: manufactured by Lipoid, containing 90% or more by mass of phosphatidylcholine
• Propylene glycol manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
• Compound Y Ethanol manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
• Compound Y 1,3-butylene glycol manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
• Compound Y 1-Pentanol manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
• the elastic modulus of the film formed by the composition for living organisms was measured using a rheometer (MCR302) and a measuring jig PP25 according to the following procedure. Using a SUS jig with a hole of 25 mm in diameter and 200 ⁇ m in thickness, a composition for living bodies of 25 mm in diameter and 200 ⁇ m in thickness was applied to a base, and the base was set in a rheometer device. Water was sprayed three times (amount of water sprayed three times: 0.3 mL) onto the composition for living bodies applied as described above using a TRUSCO finger spray (TFSB-20), and the composition was allowed to stand for 1 minute.
• TRUSCO finger spray TRUSCO finger spray
• strain dispersion measurement was performed in the range of 0.001 to 1000% at a measurement temperature of 25°C, 50% rh (relative humidity), GAP of 200 ⁇ m, frequency of 1 Hz, and Nf of 1 N. From the obtained storage modulus G' at a shear strain of 0.1%, the elastic modulus of the film formed by the composition for living organisms was evaluated according to the following evaluation criteria.
• the elastic modulus is preferably rated as B or higher.
• the strain tolerance is preferably rated as C or higher.
• the liquid viscosity of the composition for use in a living body was evaluated using a rheometer (MCR302) and a measuring jig PP25.
• the composition for use in a living body was set on the base of the device, and the liquid viscosity of the composition for use in a living body was measured under the conditions of a measuring temperature of 25°C, 50% rh (relative humidity), GAP of 1 mm, and a shear rate of 0.1 to 1000 (1/s).
• the liquid viscosity was evaluated according to the following evaluation criteria based on the viscosity at a shear rate of 0.1 (1/s).
• Viscosity at a shear rate of 0.1 (1/s) is less than 10,000 cPs.
• B Viscosity at a shear rate of 0.1 (1/s) is 10,000 cPs or more and less than 100,000 cPs.
• C Viscosity at a shear rate of 0.1 (1/s) is 100,000 cPs or more.
• a liquid crystal phase was formed within 1 minute.
• B A liquid crystal phase was formed within more than 1 minute and within 1 hour.
• C A liquid crystal phase was formed within more than 1 hour and within 24 hours.
• D No liquid crystal phase was formed even after 24 hours.
• the ratio of the scattering vector length (q/nm ⁇ 1 ) was measured to identify the liquid crystal structure.
• the liquid crystal phase was determined to be an inverted hexagonal columnar (H2) phase.
• the ratio of the scattering vector lengths of the three peaks being 1: ⁇ 3: ⁇ 4 is characteristic of the inverted hexagonal columnar (H2) phase.
• the composition of Comparative Example 1 in which the content of compound Y was more than 10 mass % based on the total mass of compound X and phospholipid, did not satisfy the desired level of strain resistance.
• the composition containing no phospholipids in Comparative Example 2 was not able to form a film, and the elastic modulus and strain resistance did not meet the desired levels.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Materials Engineering (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Hematology (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Dermatology (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=93152389

Family Applications (1)

Country Status (3)

Citations (5)

• 2024
  • 2024-04-15 JP JP2025515211A patent/JPWO2024219344A1/ja active Pending
  • 2024-04-15 WO PCT/JP2024/014935 patent/WO2024219344A1/ja not_active Ceased
• 2025
  • 2025-10-17 US US19/361,038 patent/US20260041650A1/en active Pending

Patent Citations (5)

Also Published As

Similar Documents

Legal Events